Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database
Authors:
- 1 October 2019
- journal article
- research article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 10 (5) , 869-877
Abstract
Background: Incidence of small intestinal neuroendocrine tumors (SNETs) is increasing and they now comprise the most common types of small intestinal cancer. SNETs frequently present with distant metastasis. Significant uncertainty prevails with regards to the surgical management strategies in metastatic SNETs. Therefore, we aim to analyze survival trends in metastatic SNET patients stratified by type of surgical treatment. Methods: We analyzed the data from the SEER database: Incidence − SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (1973−2014 varying). Relative survival rates (RSRs) and hazard ratios (HRs) were measured for patients diagnosed with metastatic SNET between 2000 and 2014. Treatment received was divided into two broad categories; surgical resection and no surgery and further subcategorized into local resection (LR) (surgery of the primary tumor only) and radical resection (RR) (surgery for primary tumor and metastasectomy). Results: We identified 1,138 metastatic SNET cases. Median age was 61 years. Median survival was 41 months and 5 year RSR was 72%. Age >50 years (HR 2.10, Pvs. 76%, respectively for no surgery vs. surgery group, P50 years (HR 0.37), and for primary tumor location in the duodenum (HR 0.13). Conclusions: Surgery for the primary tumor (LR or RR) significantly improved 5-year survival even in the presence of distant metastasis irrespective of primary tumor size, grade, or histology. Poor prognostic factors include, age >50 years, duodenal primary, tumor size >2 cm, and poorly differentiated histology.Keywords
This publication has 26 references indexed in Scilit:
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary SitesJournal of Clinical Oncology, 2016
- Surgical Treatment of NEN of Small Bowel: A Retrospective AnalysisWorld Journal of Surgery, 2016
- Clinical Outcomes for Neuroendocrine Tumors of the Duodenum and Ampulla of Vater:A Population-Based StudyJournal of Gastrointestinal Surgery, 2014
- Long‐Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral CenterWorld Journal of Surgery, 2011
- The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine TumorsPancreas, 2010
- Neuroendocrine TumorsJournal of the National Comprehensive Cancer Network, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursGut, 2005
- The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO ClassificationAnnals of the New York Academy of Sciences, 2004
- Hepatic neuroendocrine metastases: does intervention alter outcomes?1Journal of the American College of Surgeons, 2000